Business Wire

OSAKA-BUSINESS-DEV-AGCY

15.12.2022 06:01:35 CET | Business Wire | Press release

Share
OBDA-Aiming to create a unicorn company from Kansai that can compete globally! Announcing the Joint Branding of ”Kansai Startup Mashups” From the Three Capitals of Osaka, Kyoto, and Kobe (Hyogo)

The Osaka Business Development Agency, in cooperation with the Keihanshin Startup Ecosystem Consortium and JETRO Osaka, has jointly launched the brand, “Kansai Startup Mashups” to support startups from the Kansai region that are taking on global challenges. From this release and on, we will use "Kansai Startup Mashups" as a branding tool to promote various initiatives for startups in the Kansai region to the global market.
The first event will be held on January 25, 2023, and the call for participants begins today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005391/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Kansai Startup Mashups in Kobe, 25 / Jan / 2023. (Graphic: Business Wire)

Osaka, Kyoto, and Kobe offer an environment conducive to startups, with a concentration of bio- and healthcare-related companies, Monozukuri (manufacturing), ICT-related companies, as well as universities and research institutes.
Due to its strength environment, the "Osaka-Kyoto-Kobe(Hyogo) Consortium" was selected in 2020 as a global hub city in the Japanese government's strategy to become a world-class start-up hub, and universities, companies, and local governments are working to form an ecosystem of collaboration.

And now, with the aim to further accelerate these efforts, Osaka, Kyoto, and Kobe have jointly launched "Kansai Startup Mashups" as a unified brand for support.
The newly launched "Kansai Startup Mashups" aims to create a world-class startup ecosystem in anticipation of the 2025 Kansai Expo and the post-Kansai Expo, and to create a framework that will lead to the birth of unicorn companies from the Kansai region and the creation and support of startups that will grow to become major players.

In this initiative, the three capitals of Osaka, Kyoto, and Kobe will collaborate to link the circle of cooperation and support among universities, businesses, and government, and to disseminate Kansai startups both domestically and internationally, creating new synergies through the exchange of cutting-edge technology and domestic and international wisdom.
As part of this effort, toward the end of the fiscal year, we will be holding three events under a unified brand; ANCHOR KOBE on Wednesday, January 25, 2023 and engawa KYOTO on February 7, 2023.
On March 2, 2023, a large-scale event will be held at QUINTBRIDGE (Osaka) to unify and communicate the potential of Kyoto, Osaka, and Kobe to become the world's first to realize a future society on the occasion of the Osaka-Kansai Expo.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005391/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye